

13'
CONCL'D.
or analog[s] from the culture medium of said transformed cells or
from cell extracts of said transformed cells.

Claim 12, line 3, delete "any one of" and change
"claims" to --claim--;

lines 3-5, delete "-3, or with a protein,
peptide or analogs according to claim 6, or with antibodies,
active fragments or derivatives according to claim 11";

line 5, after "cells said", insert --modulator
is--;

lines 5-7, delete "naturally derived proteins,
peptides, analogs and derivatives thereof, said complementary
peptides, said antibodies, or said organic compounds";

line 8, after "or", insert --,--;

line 8, change "analogs" to --analog--; and

line 10, change "analogs" to --analog--.

Claim 13, lines 1 and 2, delete "treating of cells is by
administration of said protein, peptide or analogs, and said";

line 6, delete "seequence", and insert
therefor --sequence--;

lines 6 and 7, delete "a protein, peptide or
analogs thereof according to any one of claims 2, 3 and 6" and
insert therefor --said modulator--;

lines 7 and 8, delete "protein, peptide or
analogs", and insert therefor --modulator,--; and

line 8, after "cells" insert --,--.

Claim 14, lines 1-3, delete "12, wherein said treating
of said cells is by administration of said antibodies, active

fragments or derivatives thereof according to any one of claims 2, 3 and 11", and insert therefor --25--.

B²
16 (amended). A method for the modulation of the expression, proteolytic processing, bioactivity or intracellular signaling of the 26 kDa TNF in 26 kDa TNF-producing cells, comprising, treating said cells with an oligonucleotide sequence encoding a modulator of the expression, proteolytic processing, bioactivity or intracellular signaling of the 26 kDa cell-surface-bound form of TNF, said oligonucleotide sequence being capable of blocking the expression of at least one protein or peptide which interacts with the intracellular domain of the 26 kDa TNF, [according to claim 15,] wherein said oligonucleotide sequence is introduced into said cells via a recombinant virus vector of claim 13, wherein said second sequence of the virus encodes said oligonucleotide sequence.

B³
21 (amended). A pharmaceutical composition for the modulation of the expression, proteolytic processing, bioactivity or intracellular signaling of the 26 kDa TNF comprising, as active ingredient, a modulator according to [any one of] claim[s] 1[-3], or a protein, peptide or analog[s] thereof [according to claim 6, or antibodies, active fragments or derivatives thereof according to claim 11] capable of binding to or interacting with the intracellular domain of the 26kDa TNF, and a pharmaceutically acceptable excipient, carrier or diluent.

Claim 22, line 4, delete "analogs", and insert therefor --analog--.

✓
Please add the following new claims:

64
-- 31. A method for the modulation of the expression, proteolytic processing, bioactivity or intracellular signaling of the 26 kDa TNF, comprising treating cells with an antibody, active fragment or derivative according to claim 11, wherein said treating of cells comprises introducing into the cells said antibody, active fragment or derivative in a form suitable for intracellular introduction thereof, or introducing into said cells a DNA sequence encoding said antibody, active fragment or derivative in the form of a suitable vector carrying said sequence, said vector being capable of effecting the insertion of said sequence into said cells in a way that said sequence is expressed in the cells.

32. A pharmaceutical composition for the modulation of the expression, proteolytic processing, bioactivity or intracellular signaling of the 26 kDa TNF comprising, as active ingredient, an antibody, active fragment or derivative thereof according to claim 11, and a pharmaceutically acceptable excipient, carrier or diluent. --

REMARKS

Claims 1-23 and 25-32 presently appear in this case. The present amendments are being made in order to correct the improper multiply dependent claims and to place them in singly